| Ticker |
INBP
|
| CIK | 0001016504 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 225 LONG AVENUE, BUILDING 15, HILLSIDE, NJ, 07205 |
| Website | ibiopharma.com |
| Phone | 9739260816 |
| CEO | Riva Kay Sheppard |
| Employees | 150 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025HILLSIDE, NJ / ACCESS Newswire / May 14, 2025 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2025. Revenue for the quarter ended March 31, 2025 was $13.9 million ... Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024HILLSIDE, NJ / ACCESS Newswire / February 13, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2024. Revenue for the quarter ended December 31, 2024 was $12.6 ... Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024HILLSIDE, NJ / ACCESSWIRE / November 13, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2024. Revenue for the quarter ended September 30, 2024 was $13.6 million ... Integrated BioPharma Reports Results for Its Quarter and Fiscal Year Ended June 30, 2024HILLSIDE, NJ / ACCESSWIRE / September 20, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2024. Revenue for the quarter ended June 30, 2024 was $12.7 ... Integrated BioPharma Reports Results for its Quarter Ended March 31, 2024HILLSIDE, NJ / ACCESSWIRE / May 10, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2024. Revenue for each of the quarters ended March 31, 2024 and 2023 were approximately ... |
